TYK Medicines will present the research progress and results of 6 innovative drug projects at the 2023 Annual Meeting of American Association for Cancer Research (AACR 2023)
Time：2023/04/04
TYK Medicines, Inc., a biopharmaceutical company dedicated to the research and development of innovative small molecule drugs, today announced that it would participate in the 2023 Annual Meeting of the American Association for Cancer Research (AACR 2023), to be held in Orlando, Florida, USA, from April 14 to 19, 2023. During the meeting, TYK Medicines will present the research progress and results of 6 innovative drug projects in the form of posters, including TY-2699a (CDK7 inhibitor), TY-0540 (CDK2/4/6 inhibitor), TY-1054 (YAP/TEAD inhibitor), TY-4028 (Exon 20ins inhibitor), TY-2136b (ROS1/TRK/ALK inhibitor) and TY-1091 (RET inhibitor). The 6 projects to be presented are innovative small molecule drug candidates that are all independently discovered and developed by TYK Medicines. Preclinical research results demonstrated that these molecules have the potential to be “Best” in their category in terms of efficacy, safety, or metabolic properties.
Information of the posters
Project: TY-2699a (CDK7 inhibitor)
Title: TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development
Poster No.: 5981
Session: CDK and CDK inhibitors
Date: April 19, 2023
Time: 9:00 AM – 12:30 PM（EST）
Location: Poster Section 9
Project: TY-0540 (CDK2/4/6 inhibitor)
Title: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
Poster No.: 5979
Session: CDK and CDK inhibitors
Date: April 19, 2023
Time: 9:00 AM – 12:30 PM（EST）
Location: Poster Section 9
Project: TY-1054 (YAP/TEAD inhibitor)
Title: TY-1054: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo
Poster No.: 4491
Session: Molecular Targeted Therapies 2
Date: April 18, 2023
Time: 9:00 AM – 12:30 PM（EST）
Location: Poster Section 42
Project: TY-4028 (Exon 20ins inhibitor)
Title: A novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon20 insertion mutations
Poster No.: 4488
Session: Molecular Targeted Therapies 2
Date: April 18, 2023
Time: 9:00 AM – 12:30 PM（EST）
Location: Poster Section 42
Project: TY-2136b (ROS1/TRK/ALK inhibitor)
Title: Discovery of TY-2136b, a next generation of ROS1/TRK/ALK inhibitor potently inhibits acquired ROS1/ TRK /ALK mutations
Poster No.: 3400
Session: Molecular Targeted Therapies 1
Date: April 17, 2023
Time: 1:30 PM – 5:00 PM（EST）
Location: Poster Section 44
Project: TY-1091 (RET inhibitor)
Title: TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models
Poster No.: 3419
Session: Molecular Targeted Therapies 1
Date: April 17, 2023
Time: 1:30 PM – 5:00 PM（EST）
Location: Poster Section 44
For more project information or communication on project cooperation, please contact: BD@tykmedicines.com.
If you are interested in the posters, please scan the QR code below and fill the inquiry form. After review, we will send the PDF file of the posters you are interested in to your email after the AACR 2023 Annual Meeting.
About TYK Medicines
TYK Medicines, Inc. is an innovative biopharmaceutical company founded by MNC veterans in 2017, focusing on the discovery of new-generation Kinase Inhibitors to address the unmet medical needs in cancer therapy. TYK medicines has a diversified pipeline with 10+ compounds including multiple phases from the PCC stage to Phase III clinical trial. The company is committed to providing patients with more effective and safer anti-tumor drugs.
